<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00794638</url>
  </required_header>
  <id_info>
    <org_study_id>2008002</org_study_id>
    <nct_id>NCT00794638</nct_id>
  </id_info>
  <brief_title>A Phase I Clinical Trial to Assess the Safety of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Multicenter Phase I Clinical Trial to Assess the Safety of Two Consecutive Days of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SymBio Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SymBio Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety of SyB L-0501 in combination with Rituximab
      to patients with aggressive B-cell non-Hodgkin's lymphoma, and to explore the recommended
      dose for the Phase II clinical trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity</measure>
    <time_frame>Treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CR rate and the overall response rate, determination by Independent Review Committee</measure>
    <time_frame>Treatment period</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <condition>Diffuse Large B-cell Lymphoma</condition>
  <condition>Mantle Cell Lymphoma</condition>
  <condition>Follicular Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SyB L-0501</intervention_name>
    <description>The administration of SyB L-0501 90 mg/m2 or 120 mg/m2/day on Day 2 and Day 3 will be followed by 18 days of observation. In the absence of adverse events or progressive disease, treatment will be repeated up to a maximum of 6 cycles, where 1 cycle is the 21-day treatment period (3 days of administration and 18 days of observation).</description>
    <other_name>Bendamustine hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>The administration of rituximab 375 mg/m2 on Day 1 of each cycle will be followed by 18 days of observation. In the absence of adverse events or progressive disease, treatment will be repeated up to a maximum of 6 cycles, where 1 cycle is the 21-day treatment period (3 days of administration and 18 days of observation).</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Aggressive B-cell non-Hodgkin's lymphoma patients with prior therapy who satisfy the
        conditions listed below. No restrictions regarding gender.

          -  Patients with the following histologically confirmed CD20(+) B-cell non-Hodgkin's
             lymphoma:

               1. Diffuse large B-cell lymphoma

               2. Mantle cell lymphoma

               3. Transformed lymphoma

               4. Follicular lymphoma (Grade 3)

          -  Fail to CR in prior chemotherapy, or relapse following CR or recurrence following PR.

          -  Patients who are judged to carry no effect from the prior therapy (cancer
             chemotherapy, antibody therapy and radiation/ radiotherapy.

          -  Patients aged from 20 to 75 years at the time informed consent is obtained

          -  Patients with adequately maintained organ functions (e.g., bone marrow, heart, lung,
             liver, and kidney functions)

          -  Patients who can be hospitalized during the first cycle

          -  Patients capable of personally giving voluntary informed consent in writing to
             participate in the study

        Exclusion Criteria:

        Patients who meet any of the following criteria will be excluded.

          -  Patients with serious complications (hepatic or renal failure)

          -  Patients with complications or medical history of serious cardiac disease (e.g.,
             myocardial infarction, ischemic heart disease)

          -  Patients with serious gastrointestinal symptoms (e.g., severe nausea, vomiting, or
             diarrhea)

          -  Patients positive for HBs antigen, HCV antibody, or HIV antibody

          -  Patients who received other investigational drug or unapproved medication within 3
             months before registration in this study

          -  Patients who had history of hematopoietic stem cell transplantation or
             radioimmunotherapy

          -  Patients who are pregnant, of childbearing potential, or lactating

          -  Patients, whether male or female, who do not agree to contraception

          -  Patients otherwise judged by investigator or sub investigator to be unsuitable
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kensei Tobinai, MD, Ph D</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Center Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Nagoya-city</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Isehara-city</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyoto-city</city>
        <state>Kyoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2008</study_first_submitted>
  <study_first_submitted_qc>November 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2008</study_first_posted>
  <last_update_submitted>May 27, 2010</last_update_submitted>
  <last_update_submitted_qc>May 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Masahiro Furukawa</name_title>
    <organization>SymBio Pharmaceuticals Limited</organization>
  </responsible_party>
  <keyword>Non-Hodgkin's Lymphoma</keyword>
  <keyword>Diffuse Large B-Cell Lymphoma</keyword>
  <keyword>Mantle cell Lymphoma</keyword>
  <keyword>Transformed lymphoma, transformed to diffuse large B-cell lymphoma</keyword>
  <keyword>Follicular Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

